Canada needs a biotech strategy to turn scientific capital into commercial gold

At present, there is no discernible evidence of a cross-cutting or all-of-government strategy to increase the commercial dividends from the scientific capital we have accumulated in the biological sciences.

A 2017 report from Deloitte and BIOTECanada found 59 per cent of the companies said they were looking to government as their first source of future financing—the vast majority of such government funding comes through Innovation, Science, and Economic Development Canada, which is overseen by Navdeep Bains, pictured, as minister.The Hill Times photograph by Andrew Meade

Opinion

BY DAVID CRANE

September 18, 2019

TORONTO—Canada is rich in the scientific capital needed to make us a serious player in the transformative world of biotechnology. This capital is the new knowledge generated in our universities, where researchers are seeking ways in which biological technologies can be used to address the grand c...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Weekend Point of View Newsletter

A round up of the past weekâ€™s opinion writers and columnists on Saturdays and Sundays.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy